Ethypharm acquires UK drugmaker DB Ashbourne

2 October 2015

Independent French drugmaker Ethypharm says it has acquired 100% of the share capital of DB Ashbourne Group (DBA), a branded pharmaceutical business established in the UK in 2009.

DBA currently markets and supplies a range of off-patent prescription only medicines to the UK market, generating significant savings for the National Health Service and has an exciting pipeline of products in development which will be supplemented with a wide range of additional products from the Ethypharm pipeline.

The company has established a strong network of relationships with UK Clinical Commissioning Groups and a portfolio of high quality brands. In total, its products have secured an estimated £127 million ($192 million) in savings for the NHS over five years, according to Cavendish Corporate Finance, which advised on the DBA sale.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK